Ronald I. Eisenstein :: Media Clips
Myriad Gene Patent Decision Adds to Steady Erosion of IP Protection
Technology Transfer Tactics • May 01, 2010
This article discusses the recent district court ruling in the Myriad Genetics case, which serves as another major test of what is and is not patentable. Boston Intellectual Property and Life Sciences partner Ron Eisenstein provides third-party commentary in the piece.
Are Patients Misserved by Patents on Human Genes?
LA Times • April 12, 2010
In this feature article, Boston Intellectual Property and Life Sciences partner Ron Eisenstein discusses why it is important for future research to patent human genes.
Processing Bilski
BioCentury • November 16, 2009
This feature article analyzes the Bilski v. Kappos case; specifically addressing the concerns molecular diagnostic companies have regarding the pending decision. Boston intellectual property and life sciences partner Ron Eisenstein is prominently featured throughout the article providing commentary on the case and possible implications of the decision.
Painful Lessons on Patents
Inside Higher Ed • October 02, 2009
This feature article discusses the Stanford v. Roche case and quotes several experts on intellectual property law, including Boston Intellectual Property partner Ron Eisenstein, on the significant implications the decision may have on colleges and universities that seek to transform their faculty’s scholarly work into patentable inventions.
Use Proactive Measures to Prevent Contentious IP Disputes With Researchers August 2009
Technology Transfer Tactics • September 01, 2009
This feature article discusses effective, proactive ways to avoid contentious disputes over intellectual property (IP) with researchers. Boston Intellectual Property partner Ron Eisenstein is quoted throughout the piece.
Use proactive measures to prevent contentious IP disputes with researchers
Technology Transfer Tactics • August 01, 2009
Article coauthored by Ron Eisenstein.
Heavy Drugs
Drug Discovery and Development • May 01, 2009
This feature article addresses the inroads biotech companies are making in clinical trials and with the U.S. Patent and Trademark Office (PTO) with specialized versions of established pharmaceuticals which are demonstrating longer metabolism cycles, improved safety, and greater effectiveness than the pioneer drugs. Boston intellectual property and biotech partner Ron Eisenstein provides commentary in the piece.
Patent costs, paperwork to spiral under ‘complex’ new USPTO rules
Technology Transfer Tactics • October 01, 2007
Article including comments from Ron Eisenstein about the USPTO rules.
PTO Narrows the Fairway
BioCentury • August 27, 2007
Article detailing a recent ruling from the U.S. Patent and Trademark office that limits the number of continuations and claims allowed for patent applications, with commentary from Ronald Eisenstein discussing the time-consuming process of patent applications and providing the details of filing a patent application.
Patent Rules to Aid Generics
Washington Times • August 24, 2007
Article including comments from Ron Eisenstein about how patent rule changes will effect biotechnology companies, universities, and nonprofit organizations.
